SCHEMBL4659396

SCHEMBL4659396

COC(=O)c1ccc(NC(=O)CCc2ccc(OCCCCCCc3ccccc3)cc2)cc1C(=O)OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 1/20 0.54
RAB9A P51151 3/20 0.52
KDM4E B2RXH2 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
LTA4H P09960 1/20 0.51
EPHX2 P34913 1/20 0.51
S1PR1 P21453 3/20 0.50
NPC1 O15118 2/20 0.50
CNR1 P21554 1/20 0.50
CNR2 P34972 1/20 0.50
S1PR3 Q99500 1/20 0.50
S1PR5 Q9H228 1/20 0.50
NR1H4 Q96RI1 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4656898 1.00 FFAR1 (0.54) FFAR1ALDH1A1HPGDRAB9AKDM4E
SCHEMBL4658183 0.99 FFAR1 (0.55) FFAR1ALDH1A1HPGDRAB9AKDM4E
SCHEMBL4659021 0.92 FFAR1 (0.52) FFAR1ALDH1A1HPGDRAB9AKDM4E
SCHEMBL4657775 0.91 RAB9A (0.58) FFAR1ALDH1A1HPGDRAB9AKDM4E
SCHEMBL4658004 0.91 FFAR1 (0.51) FFAR1ALDH1A1HPGDRAB9AKDM4E
SCHEMBL4658408 0.91 MEN1 (0.51) FFAR1ALDH1A1HPGDRAB9AKDM4E
SCHEMBL4659019 0.89 ALDH1A1 (0.49) FFAR1ALDH1A1HPGDRAB9AKDM4E
SCHEMBL4659416 0.89 RAB9A (0.48) ALDH1A1HPGDRAB9AKDM4ECYP1A2
SCHEMBL4659441 0.89 RAB9A (0.48) ALDH1A1HPGDRAB9AKDM4ECYP1A2
SCHEMBL4657977 0.89 FFAR1 (0.57) FFAR1RAB9ALTA4HEPHX2S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1391199-B1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2008-12-10 EP disclosed
US-20070088027-A1 Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2007-04-19 US disclosed
US-20070088027-A1 Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2007-04-19 US disclosed
US-7179817-B2 Carboxylic acid derivatives and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
US-7179817-B2 Carboxylic acid derivatives and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
US-20040224941-A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-11 US disclosed
EP-1391199-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-02-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088027-A1 Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient EDF1, FFAR1, EDNRA FFAR1 2/4885ALDH1A1 411/4885HPGD 363/4885
US-20040224941-A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient EDF1, FFAR1, VCAM1 FFAR1 2/4885ALDH1A1 261/4885HPGD 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.